Bay Labs, Inc.

baylabs.io

Bay Labs applies deep learning technology to cardiovascular imaging to help in diagnosis and management of heart disease. We are an early-stage healthcare startup backed by top venture capital firms and the National Science Foundation. We created Bay Labs in 2013 to push the limits of deep learning to make an impact on healthcare. Our mission is to democratize medical imaging for greater patient outcomes and wellness worldwide. By improving access, value, and quality to medical imaging, we aim to promote and advance healthcare in both the developed and developing world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

TREATMENT TO EXPAND GLOBAL LIBRARY OF MEDICINE WITH DERMATOLOGIC DISEASES

Treatment.com International Inc. | January 05, 2022

news image

Treatment.com International Inc. a healthcare AI technology company, has entered into a research project agreement with the University of Minnesota to add more than 220 dermatologic diseases to their proprietary, responsive AI engine known as the Global Library of Medicine (GLM). The addition of these diagnoses will bring another level of accuracy and specificity to the GLM, enhancing soon-to-be-released products such as the Treatment Mobile app, which is set for release this month.
Read More

Business Insights, PHARMACY MARKET

VISIOX PHARMA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR GLAUCOMA

Visiox Pharma LLC | December 09, 2022

news image

Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, today announced that it has received notification from the U.S. Food and Drug Administration that the agency has completed its filing review and accepted for filing the New Drug Application for PDP-716 for the treatment of glaucoma. The FDA has assigned a Prescription Drug User ...

Read More

REASONS FOR HOPE: THE DRUGS, TESTS AND TACTICS THAT MAY CONQUER CORONAVIRUS

Times Now | April 14, 2020

news image

With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the virus. While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinic...

Read More

Business Insights

QUALIGEN THERAPEUTICS ACQUIRES MAJORITY STAKE IN INFECTIOUS DISEASE DIAGNOSTICS TECHNOLOGY COMPANY NANOSYNEX

Qualigen Therapeutics, Inc. | June 03, 2022

news image

Qualigen Therapeutics, Inc. a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology. NanoSynex’s award winning technology is an Antimicrobial Susceptibility Testing (AST) platform that aims to ...

Read More
news image

Business Insights

TREATMENT TO EXPAND GLOBAL LIBRARY OF MEDICINE WITH DERMATOLOGIC DISEASES

Treatment.com International Inc. | January 05, 2022

Treatment.com International Inc. a healthcare AI technology company, has entered into a research project agreement with the University of Minnesota to add more than 220 dermatologic diseases to their proprietary, responsive AI engine known as the Global Library of Medicine (GLM). The addition of these diagnoses will bring another level of accuracy and specificity to the GLM, enhancing soon-to-be-released products such as the Treatment Mobile app, which is set for release this month.
Read More

news image

Business Insights, PHARMACY MARKET

VISIOX PHARMA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR GLAUCOMA

Visiox Pharma LLC | December 09, 2022

Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, today announced that it has received notification from the U.S. Food and Drug Administration that the agency has completed its filing review and accepted for filing the New Drug Application for PDP-716 for the treatment of glaucoma. The FDA has assigned a Prescription Drug User ...

Read More
news image

REASONS FOR HOPE: THE DRUGS, TESTS AND TACTICS THAT MAY CONQUER CORONAVIRUS

Times Now | April 14, 2020

With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the virus. While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinic...

Read More
news image

Business Insights

QUALIGEN THERAPEUTICS ACQUIRES MAJORITY STAKE IN INFECTIOUS DISEASE DIAGNOSTICS TECHNOLOGY COMPANY NANOSYNEX

Qualigen Therapeutics, Inc. | June 03, 2022

Qualigen Therapeutics, Inc. a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology. NanoSynex’s award winning technology is an Antimicrobial Susceptibility Testing (AST) platform that aims to ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us